SELLAS Life Sciences Group, Inc. (SLS) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.
The consensus price target is $2.80 (low: $2.40, high: $3.20), representing a downside of 42.4% from the current price $4.86.
Analysts estimate Earnings Per Share (EPS) of $-0.54 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.05 vs est $-0.54 (beat +90.6%). 2025: actual $-0.25 vs est $-0.26 (beat +3.8%). Analyst accuracy: 0%.
SLS Stock — 12-Month Price Forecast
$2.80
▼ -42.39% Downside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for SELLAS Life Sciences Group, Inc., the average price target is $2.80, with a high forecast of $3.20, and a low forecast of $2.40.
The average price target represents a -42.39% change from the last price of $4.86.
Highest Price Target
$3.20
Average Price Target
$2.80
Lowest Price Target
$2.40
SLS Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to SELLAS Life Sciences Group, Inc. in the past 3 months
EPS Estimates — SLS
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.05
vs Est –$0.54
▲ 962.7% off
2025
Actual –$0.25
vs Est –$0.26
▲ 4.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — SLS
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
